Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 USD | -0.66% | +14.59% | -57.11% |
26/04 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
12/04 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Evolution of the average Target Price on Revance Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Revance Therapeutics, Inc.
Goldman Sachs | |
Needham & Co. | |
Piper Sandler | |
Mizuho Securities | |
HC Wainwright | |
Barclays | |
Morgan Stanley | |
BNP Paribas Exane | |
Cowen | |
Wells Fargo Securities |
EPS Revisions
- Stock Market
- Equities
- RVNC Stock
- Consensus Revance Therapeutics, Inc.